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Molecularly speciﬁc detection of bacterial lipoteichoic acid for
diagnosis of prosthetic joint infection of the bone
Julie E. Pickett1, John M. Thompson2, Agnieszka Sadowska3, Christine Tkaczyk3, Bret R. Sellman3, Andrea Minola4, Davide Corti4,
Antonio Lanzavecchia5, Lloyd S. Miller2,6,7 and Daniel LJ Thorek1,8
Discriminating sterile inﬂammation from infection, especially in cases of aseptic loosening versus an actual prosthetic joint
infection, is challenging and has signiﬁcant treatment implications. Our goal was to evaluate a novel human monoclonal antibody
(mAb) probe directed against the Gram-positive bacterial surface molecule lipoteichoic acid (LTA). Speciﬁcity and afﬁnity were
assessed in vitro. We then radiolabeled the anti-LTA mAb and evaluated its effectiveness as a diagnostic imaging tool for detecting
infection via immunoPET imaging in an in vivo mouse model of prosthetic joint infection (PJI). In vitro and ex vivo binding of the
anti-LTA mAb to pathogenic bacteria was measured with Octet, ELISA, and ﬂow cytometry. The in vivo PJI mouse model was
assessed using traditional imaging modalities, including positron emission tomography (PET) with [18F]FDG and [18F]NaF as well as
X-ray computed tomography (CT), before being evaluated with the zirconium-89-labeled antibody speciﬁc for LTA ([89Zr]SAC55).
The anti-LTA mAb exhibited speciﬁc binding in vitro to LTA-expressing bacteria. Results from imaging showed that our model could
reliably simulate infection at the surgical site by bioluminescent imaging, conventional PET tracer imaging, and bone morphological
changes by CT. One day following injection of both the radiolabeled anti-LTA and isotype control antibodies, the anti-LTA antibody
demonstrated signiﬁcantly greater (P < 0.05) uptake at S. aureus-infected prosthesis sites over either the same antibody at sterile
prosthesis sites or of control non-speciﬁc antibody at infected prosthesis sites. Taken together, the radiolabeled anti-LTA mAb, [89Zr]
SAC55, may serve as a valuable diagnostic molecular imaging probe to help distinguish between sterile inﬂammation and infection
in the setting of PJI. Future studies are needed to determine whether these ﬁndings will translate to human PJI.
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INTRODUCTION
Total joint arthroplasty is a common orthopedic surgical
procedure with not only signiﬁcant beneﬁts but also challenging
complications, especially related to infection.1 Prosthetic joint
infection (PJI), which is an infection involving the implant and
adjacent bone and joint tissues, affects up to 2% of all primary
arthroplasties, resulting in an estimated 25 000 cases and costs
exceeding $3.2 billion.2 The current standard of care therapy for
chronic PJI of the hip and knee involves complete removal of all
infected tissue and implants with eventual hardware replacement
after prolonged antibiotic therapy. Successful treatment occurs in
(65–90)% of cases, but failure often requires further treatments,
surgeries, or even amputation.3,4 As the total number of total hip
and total knee arthroplasties in the United States is projected to
exceed 4 million by the year 2030, these complications will only
become more common.2
Differentiating PJI from sterile inﬂammation in the postopera-
tive period remains a challenge for contemporary diagnostic
techniques, such as commonly used imaging modalities, labora-
tory tests, and bacterial cultures.5 Noninvasive imaging modalities
are attractive options, as they offer the potential for diagnosing,
monitoring, and assessing treatment longitudinally if sufﬁcient
sensitivity and resolution can be achieved. X-ray and magnetic
resonance imaging (MRI) reveal gross morphological changes but
unfortunately produce implant-related artifacts (especially invol-
ving metallic implants) that obscure relevant changes in the
surrounding tissue.
Positron emission tomography (PET) generates three-
dimensional (3D) tracer concentration images with the potential
for excellent sensitivity and without implant artifacts suffered by
computed tomography (CT) and MRI. The sensitivity of this
modality has the ability to detect infectious burden and molecular
changes that occur prior to macroscopic anatomical alterations.6
Widely used conventional tracers, including [18F]FDG (2-ﬂuoro-2-
deoxy-D-glucose), [18F]NaF, and [68Ga]citrate, have been investi-
gated for PET localization and evaluation of PJI with variable
success.7–10 However, current imaging approaches assess indirect
markers of infection—methods that are often hindered by low
speciﬁcity and/or sensitivity—rather than directly targeting the
infectious agent.
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An alternative approach to improve diagnosis of PJI may be to
use targeted probes, such as antibodies or peptides.11 Radiola-
beled antibodies for immunoPET have long been used for
investigational and clinical studies for oncological applications.12
Prior infection-related investigations have focused on antibodies
to human targets such as white blood cells or other indirect
markers of infection.7,8 In this study, we assessed an antibody
directly targeting Gram-positive bacteria such as Staphylococcus
aureus and Staphylococcus epidermidis (the bacteria commonly
responsible for PJI). The antibody is directed against lipoteichoic
acid (LTA), a surface-associated component of the cell wall of
Gram-positive bacteria. Expressed by the bacteria at high levels,
this antigen is a promising target for directed imaging and
therapeutic agents. By directly targeting the infectious agent, we
demonstrate improved diagnostic capabilities of noninvasive
imaging, which may guide improved patient management.
RESULTS
In vivo model of a S. aureus PJI
Previous work with other bioluminescent strains has demon-
strated that bioluminescent signals closely approximate and
correlate with the bacterial burden, as measured by ex vivo
colony-forming unit (CFU) counting.13–17 In vivo bioluminescence
imaging (BLI) of mice demonstrated that the average signal from
the S. aureus-infected postoperative legs (4.3 ± 0.9) × 104 p/s/cm2/
sr (n= 10) was greater than for mice that had surgery performed
without bacterial inoculation (1.4 ± 0.09) × 103 p/s/cm2/sr (n= 10,
P < 0.000 6) (Fig. 1a, b). The infection remained locally at the
original site of inoculation as bioluminescent signals were not
detected above background at other regions of the body. In
addition, this model of PJI resulted in expansion and damage of
the distal femur as the infection progressed, which was conﬁrmed
by CT and high-resolution X-ray imaging (Fig. 1c).16 The
anatomical changes in the distal femur of the S. aureus-infected
postoperative legs can be seen clearly compared with the
contralateral, non-operative leg.
[18F]FDG imaging
[18F]FDG is a glucose analog that is taken up by cells with high
glucose avidity, including tumors, inﬂammation, and bacteria.
Volumes of interest were deﬁned manually around areas of focal
[18F]FDG uptake in the distal femurs of both the postoperative and
contralateral, non-operative legs of the mice after saline injection
or S. aureus infection. To control for variability in mouse size, data
are presented as averages of the fold increase of the postoperative
leg measurement over the contralateral, non-operative leg. In the
S. aureus-infected postoperative legs, there was a large mean
increase (9.8 ± 0.4, n= 8) compared with a doubling (2.1 ± 0.2, n=
4) for the sterile postoperative legs (Fig. 2). We see a signiﬁcant
uptake of in S. aureus-infected surgical postoperative legs
compared to contralateral non-operative legs (P < 0.000 1), sug-
gesting that the probe speciﬁcally localized to infected surgical
sites. However, the glucose avidity of metabolically active cells,
such as immune cells at sites of inﬂammation following sterile
implantation surgery, complicate diagnosis of infection.18
Fig. 1 In vivo bioluminescent imaging in a mouse model of PJI. A titanium Kirschner-wire was surgically placed in the mouse femur with or
without an inoculum of a bioluminescent S. aureus strain in the knee joint prior to closure. a Representative in vivo bioluminescent signals at
the S. aureus-infected postoperative site. b Maximum radiance values for individuals (mean ± S.E.M.) with sterile control implants or S. aureus-
infected postoperative distal femur sites at a representative time point (1 400 ± 90 vs 43 000 ± 9 000, respectively). c CT (top) and X-ray
(bottom) imaging demonstrating the location of the Kirschner-wire (false-colored pink in the CT image) in the distal femur. *P < 0.000 6
Fig. 2 [18F]FDG uptake in the mouse model of PJI. a Representative [18F]FDG PET images (arrows indicate the operative site on the distal
femur). b Mean ± S.E.M. fold increase of the [18F]FDG signal in the sterile vs S. aureus-infected, operative legs over the contralateral, non-
operative legs (2.1 ± 0.2 vs 9.8 ± 0.4, respectively). *P < 0.000 1
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Bone scans with [18F]NaF
[18F]NaF is incorporated within the bone matrix at sites of
increased bone turnover such as that with natural growth at the
physis as well as at sites of reactive bone changes that occur in
response to infection.19–22 [18F]NaF uptake was evaluated in this
PJI model, and greater [18F]NaF uptake was observed in the S.
aureus-infected postoperative legs (3.9 ± 0.4 fold, n= 9) than in
the sterile postoperative legs (1.4 ± 0.06 fold, n= 4, P < 0.000 3)
(Fig. 3a, b). Of note, the fold increase observed in the sterile
postoperative leg compared with the contralateral non-operative
leg was >1.0, which was likely due to modest bone turnover from
the naturally occurring inﬂammatory response from the implant
alone.
CT imaging
Femoral volumes were deﬁned from CT scan data. To control for
variability in the size of the femurs between the individual mice,
data are presented as averages of the fold increase of the
measurement of the postoperative femur over the contralateral,
non-operative femur. The femur volumes of S. aureus-infected
postoperative legs had a doubling of bone volume for the entire
femur (2.1 ± 0.06, n= 8) compared with sterile, postoperative legs,
which had a slight increase over their non-operative counterpart
(1.2 ± 0.03, n= 4, P < 0.000 1), the large size and structural
differences of which can be seen in representative scans
(Fig. 4a–e). Taken together, CT data analysis showed that the S.
aureus-infected operative legs had a marked expansion of the
femur volume compared with sterile postoperative legs, which is
consistent with our previous observations.16,23
Speciﬁcity of the anti-LTA monoclonal antibody (mAb)
In order to speciﬁcally measure the infectious entity itself, we
developed an immunoPET agent against LTA, a cell-surface
component of Gram-positive bacteria. An anti-LTA mAb (SAC55)
was identiﬁed from memory B cells isolated from a patient
recovering from an S. aureus skin infection. This human
immunoglobulin G1 (IgG1) was evaluated for binding speciﬁcity
and selectivity for LTA-positive strains of pathogenic bacteria with
clinical signiﬁcance. Afﬁnity measurements by Octet of SAC55
binding to immobilized LTA showed strong binding for the target
(Fig. 5a). SAC55 was also found by whole-cell enzyme-linked
immunosorbent assay (ELISA) to bind speciﬁcally to LTA-positive
bacteria, including S. aureus and S. epidermidis, but not to Gram-
negative bacteria (speciﬁcally Escherichia coli and Pseudomonas
aeruginosa), whereas the control IgG did not bind to any of the
LTA-negative bacterial species tested (Fig. 5b)
SAC55 also bound to in vitro grown S. aureus and S. epidermidis
as measured by ﬂow cytometry in the presence of human sera
(Fig. 5c), thus indicating that the binding epitope for this anti-LTA
mAb is not obscured by the presence of human sera. Similarly, this
anti-LTA mAb retained binding to the bacteria ex vivo, indicating
that LTA is expressed, and its epitope is accessible for antibody
binding on bacteria harvested from infected mice (Fig. 5d). These
results indicate that SAC55 is a valid candidate to speciﬁcally
detect LTA-expressing bacteria in an infected animal.
Radiolabeling and immunoPET imaging of SAC55
Anti-LTA and isotype control IgG were covalently conjugated to
deferoxamine (DFO) via an isothiocyanate-amine reaction cova-
lent linkage and subsequently radiolabeled with zirconium-89.
Post-puriﬁcation radioTLC conﬁrmed purity by showing the >98%
radiopurity of the labeled constructs (Fig. 6).
ImmunoPET imaging of infected implant mice with [89Zr]SAC55
and control [89Zr]IgG, as well as control sterile implant mice was
conducted over 168 h. On day 1 post injection, animals receiving the
anti-LTA antibody had a greater signal uptake ratio than infected
implant mice receiving control IgG or sterile implant mice receiving
the anti-LTA antibody (Fig. 7a). This was a surprising ﬁnding as the
Fig. 3 [18F]NaF uptake in the mouse model of PJI. a Representative [18F]NaF PET images (arrows indicate the operative site on the distal
femur). b Mean ± S.E.M. fold increase of the [18F]NaF signal in the sterile vs S. aureus-infected, operative legs over the contralateral, non-
operative legs (1.4 ± 0.06 vs 3.9 ± 0.4, respectively). *P < 0.000 3
Fig. 4 CT imaging in the mouse model of PJI. a–d CT imaging of the femur (a, c) and corresponding volumetric measurement (b, d) shown for
representative sterile (a, b) and S. aureus-infected (c, d) mice. e Mean ± S.E.M. fold increase of the femur volumes in the sterile vs S. aureus-
infected operative legs over the contralateral, non-operative legs (1.2 ± 0.03 vs 2.1 ± 0.06, respectively). *P < 0.000 1
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pharmacokinetics of full IgG, which may circulate for days or weeks,
are such that the antibody typically accumulates over days as
background signal reduces. As shown in the representative animals
in Fig. 7b, early time points enabled clear distinction of the infected
site using the speciﬁc antibody over the non-speciﬁc control or in
the sterile infection model (P < 0.05 up to day 3). The speciﬁc
contrast decreased over the 7 days of the experiment as non-
speciﬁc zirconium-89 uptake in the skeleton increased.
A correlation analysis between of the uptake ratio of [89Zr]-
labeled antibody and [18F]FDG and [18F]NaF was performed, in
addition to the SUVmean values of [89Zr]-labeled antibody and BLI
in the leg that had undergone surgical implantation of the pin.
There was no signiﬁcant correlation between the different PET
imaging tracers [with R2 values (and two-tailed P-values) of 0.292 2
(0.069 6) and 0.137 4 (0.212 5), respectively]. A weak but statisti-
cally signiﬁcant correlation between the standardized uptake
values (SUVmean) and the bioluminescent signal yielded an R2
value of 0.588 8 (P= 0.003 6). These correlation results indicate
speciﬁcity of the antibody-targeted approach with bacterial
luminescence, while there is a lack of direct association between
Fig. 5 Anti-LTA mAb characterization. Experimental anti-LTA antibody (SAC55) was analyzed for binding characteristics by several methods
against species-matched isotype control IgG (R347). a koff, kon, and KD were assessed by Octet for SAC55 against LTA. b Selective binding of
SAC55 to Gram-positive bacteria (S. aureus and S. epidermidis) but not Gram-negative bacteria (E. coli and P. aeruginosa) is assessed, as well as an
absence of binding by the control antibody R347. c Flow cytometry of in vitro grown S. aureus reveals selective binding, with the distinction
between groups improved by addition of human sera. d Flow cytometry of S. aureus harvested from mouse blood shows selective binding of
SAC55 to Gram-positive bacteria, following in vivo passage.
Fig. 6 Radiopurity. Radiopurity of the immunoPET conjugates were determined by radio-instant thin layer chromatography.After puriﬁcation,
the activity for both SAC55 and R347 conjugates is retained at the origin, with no evidence of free zirconium migrating up the plate, indicating
that injected material does not contain free zirconium-89.
Diagnosis of prosthetic joint infection
Pickett et al.
4
Bone Research  (2018) 6:13 
radiolabeled probes. While further work is required, this data
indicate that a bacterial-speciﬁc tracer such as [89Zr]SAC55 may
have considerable value in evaluating preclinical models and
could assist in detection of PJI in the clinical setting.
DISCUSSION
Diagnosis of PJI in the setting of background inﬂammation is
complex. Commonly used X-ray, CT, and MRI may not reliably
distinguish sterile joint loosening from infection. Development of
a bacteria-speciﬁc imaging probe would allow for differentiation
of infectious processes from sterile inﬂammation. The sensitivity of
PET imaging would be particularly valuable in settings of low
bacterial burden. Here we evaluated a human mAb directed
against LTA, a component of the cell wall of Gram-positive
bacteria (implicated in >60% of PJI).24 The high-afﬁnity mAb,
SAC55, exhibited speciﬁc binding to Gram-positive S. aureus and S.
epidermidis not only after in vitro growth (Fig. 5b, c) but also after
in vivo passage in mice (Fig. 5d). With the intent to speciﬁcally and
noninvasively image the bacterial pathogen directly and to
facilitate improved sensitivity of detection, we have developed
[89Zr]SAC55. This immunoPET agent provided statistically signiﬁ-
cant distinction of both the presence of infection over sterile
implant sites as well as targeted over non-speciﬁc antibody.
Typically, immunoPET imaging has been conducted several
days after administration as background blood pool clearance of
the antibody is required to distinguish the site of interest.
Consequently, we utilized the relatively long-lived isotope
Fig. 7 Uptake of 89Zr-labeled anti-LTA and control antibodies in vivo. Anti-LTA (SAC55) and control IgG mAbs were conjugated to DFO,
radiolabeled with 89Zr, and injected into mice with (infected) and without (sterile) S. aureus inoculation in the in vivo model of PJI. a The ratio
of postoperative leg signal to contralateral, non-operative leg signal is plotted as mean ± S.E.M. b, c Representative PET scans at day 1 after
injection of [89Zr]SAC55 or [89Zr]IgG mAb depicted sagitally (b) and axially (c). d Representative X-ray images of the same mice, depicting
implant location and morphological bone changes. *P < 0.05, **P < 0.01.
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zirconium-89. However, we observed that the signal ratio of [89Zr]
anti-LTA mAb at the S. aureus-infected postoperative legs vs
contralateral, non-operative legs was greatest at 1 day after
administration. We speculate that this may be in part due to the
improved immune system recognition of the bacteria after
antibody binding, leading to the clearance of both the bacteria
and the tracer from the site. Shortening the time between
injection and imaging would improve the logistics of utilizing this
technology in patients and may allow for the use of shorter-lived
isotopes, resulting in reduced radiation exposure.
SAC55 was compared to conventional PET tracers and CT
imaging. [18F]FDG has previously been explored as a non-speciﬁc
probe for evaluating PJI with varying success.18 PET provides insight
into the metabolism of host tissue, as cells that utilize radioglucose
trap the tracer locally. PET provides millimeter-scale tomographic
images of tracer distribution throughout the whole body, while CT
provides higher-resolution attenuation maps of use for anatomical
localization, abnormal tissue ﬁndings, and to identify sites of bone
degeneration. We have shown that FDG uptake in the surgical distal
femur of infected mice was much greater than that of the
contralateral, nonsurgical femur and also correlated with the BLI
ﬁndings in the surgical vs nonsurgical sites. However, we also found
increased FDG uptake in the sterile surgical leg (Fig. 2b), suggesting
that some uptake is due to inﬂammation caused by the surgery.
While [18F]FDG may easily identify robust PJI, indolent infections
with low bacterial burdens, or those being actively treated, may be
indistinguishable from sterile background inﬂammation.25
[18F]NaF has previously been used to assess the impacts of
tuberculosis and total hip arthroplasty, as it is taken up by the
surrounding bone matrix at these degenerative sites.19–21 While
gross morphological changes were seen in this study after months
of infection in the mouse model, such changes may not be
distinguishable in the absence of long-term infection. Remodeling
of the bone due to sterile inﬂammation may again preclude the
distinction of indolent infection vs sterile inﬂammation, as
conﬁrmed when comparing the sterile implant to the contralateral
knee (Fig. 3b). While CT and [18F]NaF PET may not aid in early
diagnosis of PJI, they may be useful once substantial remodeling
has occurred. A correlation analysis across the PET imaging probes
and that of bacterial-speciﬁc bioluminescence indicates the
speciﬁcity of the antibody-targeted PET imaging approach.
This study was limited in part by the fact that the physes in mice
are continually active and do not fuse, as occurs in humans. This
results in sustained bone turnover and signal at the ends of the
long bones by both [18F]FDG and [18F]NaF.26 However, this
confound was controlled for by comparing postoperative joints to
their contralateral, non-operative sites, which also have an active
physis. There are also practical considerations that are relevant
when comparing different imaging tracers or modalities of
translational import. While it is ﬁnding greater acceptance in the
cancer-imaging realm, [89Zr]-labeled antibody PET imaging is still
performed at only a small number of sites worldwide. CT imaging,
[18F]FDG, and [18F]NaF PET are routinely performed and can provide
same day (outpatient) logistics. Often with mAbs, the long
clearance time after injection requires several days between
administration and imaging. Intriguingly, here we have observed
that the optimal [89Zr]SAC55 imaging time point was only 24 h after
injection. BLI of bacteria in small animals is generally feasible but
requires genetic manipulation of the infectious organism that may
alter properties of the model and is not suitable for larger animal
models or human use (as the light-producing proteins are highly
immunogenic and provide signal sufﬁcient for superﬁcial imaging).
In conclusion, we have demonstrated the ability of an anti-LTA
mAb immunoPET imaging probe to discriminate infection from
non-speciﬁc inﬂammation in a preclinical mouse model of PJI. We
have further highlighted the potential and shortcomings of
conventional PET tracers in imaging of these models. We plan to
examine the role of molecularly speciﬁc imaging to monitor efﬁcacy
of the SAC55 mAb as a targeted therapeutic to clear LTA-positive
infections. Investigation in larger animal models and in patients is
needed to determine whether the [89Zr]SAC55 probe can be
translated to diagnose PJI and other infections in clinical practice.
MATERIALS AND METHODS
Antibody development
The monoclononal antibody (mAb) speciﬁc for LTA (anti-LTA,
SAC55) was identiﬁed from IgG+ memory B cells selected from a
patient convalescing from a S. aureus skin infection (erysipelas), as
previously described.27 A human IgG1 mAb (R347, directed
against an unrelated HIV-gp120 antigen) was used as an isotype
control human IgG1.28
Antibody labeling
The heterobifunctional chelate, p-SCN-Bn-DFO, was from Macro-
cyclics (Dallas, TX). Reagents and chemicals were from Sigma-
Aldrich (St. Louis, MO) unless otherwise stated. Zirconium-89 was
from the Mallinckrodt Institute of Radiology (Washington Uni-
versity Medical School, St. Louis, MO).
Conjugating the chelator (DFO) to the antibody
To antibody in 0.1 mol · L−1 HEPES at pH 8.5, 10 µL of DFO in
dimtethyl sulfoxide (233.3 µmol · L−1) was added three times
followed by mixing to a ﬁnal DFO:antibody ratio of 7:1. The
reaction was mixed at room tempterature for 30–60min. Excess
unreacted DFO was removed by centrifugation using Amicon Ultra
0.5 mL Centrifugal Filters Ultracel 50 K Regenerated Cellulose
50000 NMWL (EMD Millipore, Billerica, MA).
Labeling with 89Zr
To zirconium-89, an excess of 1 M oxalic acid was added. Slowly
Na2CO3 was added to bring the pH to 7–7.5.
89Zr was added to the
DFO-conjugate antibody, and the reaction was mixed at room
temperature for 40 min. To chelate free 89Zr, 50 mmol · L−1 EDTA,
pH 5, was used and removed by centrifugation using sterile saline
in Amicon Ultra 0.5 mL Centrifugal Filters Ultracel 50 K Regener-
ated Cellulose 50000 NMWL (EMD Millipore, Billerica, MA). Instant
thin layer chromatography (ITLC) was performed using silica
impregnated ﬁlter paper (Pall Corporation, Port Washington, NY).
The ITLC was run in 50 mmol · L−1 EDTA, pH 5, and subsequently
imaged and quantiﬁed using the Phosphorimager and the
AutoQuant software package, respectively (Packard, PerkinElmer,
Hopkinton, MA). For both speciﬁc SAC55 and control antibodies,
speciﬁc activities were in the range of 1.7–2.2 mCi · g−1.
Bacteria and inoculum preparation
Community-acquired methicillin-resistant Staphylococcus aureus (CA-
MRSA) strain SF8300 USA300 CA-MRSA was kindly provided by Binh
Diep of UCSF (San Francisco, CA). Staphylococcus epidermidis strain
1457, P. aeruginosa strain PAO1, and Escherichia coli strains were
obtained from American Type Culture Collection (ATCC, Manassas,
VA). S. aureus and S. epidermidis were streaked for isolation on
trypticase soy agar (TSA) plates (VWR International, Radnor, PA) and
a single colony was inoculated into tryptic soy broth (TSB) and
grown overnight. P. aeruginosa was grown overnight on a TSA plate
and resuspended in TSB to the appropriate optical density (OD)600
nm. A bioluminescent CA-MRSA strain (SAP231) was derived from the
parent NRS384 strain as previously described.13 SAP231 possesses
the bioluminescent lux construct in the bacterial chromosome so
that only live and actively metabolizing bacteria will produce
light, and light production is maintained in all progeny without
selection. Mid-logarithmic phase bacteria were obtained after
overnight culture in TSB at 37 °C with shaking (240 r · min−1)
followed by a 2 h subculture at 1:50 dilution. The desired inoculum
of bacteria was washed and reconstituted in sterile phosphate-
buffered saline (PBS).
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Whole-cell ELISA binding
Bacteria from an overnight culture were washed in ice-cold PBS
(VWR International) and adjusted to an OD600 nm ~ 0.1 in ice-cold
PBS. ELISA plates (Nunc MaxiSorp, Nalge Nunc International,
Rochester, NY) were coated with 100 µL of bacteria and incubated
overnight at 4 °C. Plates with S. aureus were then blocked with 400
µg · mL−1 rabbit IgG (Sigma-Aldrich, St. Louis, MO), and plates with
other bacterial species were blocked with 1% bovine serum
albumin (BSA; Sigma-Aldrich, St. Louis, MO) in PBS for 2 h at 4 °C
and then washed 3× with 0.1% Tween-20 (vol/vol) in PBS (PBST).
Serial dilutions of 100 µL of SAC55 or isotype control R347 were
then applied to the plates and incubated for 2 h at 4 °C. The plates
were washed 3 times with PBST, and bound antibody was detected
with 100 µL of 1 µg · mL−1 horseradish peroxidase-conjugated goat-
anti-human IgG (Jackson Immunoresearch Laboratory, West Grove,
PA) and 3,3′,5,5′-tetramethylbenzidine substrate (KPL, SeraCare,
Milford, MA). The reaction was stopped after 10min with 100 μL 0.2
mol · L−1 H2SO4, and the OD450 was measured in a spectro-
photometer (Molecular Devices, Sunnyvale, CA).
Flow cytometry—in vitro grown bacteria
Flow cytometry on in vitro grown bacteria was conducted on
overnight bacterial cultures washed in ice-cold PBS, adjusted to
OD600 nm ~ 0.2, and blocked with 10% or 50% human sera for 1 h
at 4 °C. After one wash in PBS with 0.1% BSA, pellet was incubated
with 100 µL of Alexa Fluor 488 (ThermoFisher Scientiﬁc, Waltham,
MA)-labeled SAC55or R347 at 10 µg · mL−1 in PBS in the presence
of 10% or 50% human sera. Following two washes, mAb binding
was quantiﬁed by ﬂow cytometry with an LSRII ﬂow cytometer
(Becton-Dickinson, Franklin Lakes, NJ).
Flow cytometry—in vivo grown bacteria
Six-to-eight-week-old female CD1 mice (Harlan, Indianapolis, IN)
were infected by intraperitoneal injection of 5 × 108 CFU of S.
aureus or S. epidermidis. Four hours postinfection, the animals were
euthanized, and blood obtained after cardiac puncture was
pooled from 4 mice into ice-cold sodium citrate at 0.35%
(weight:vol) ﬁnal concentration. Eukaryotic cells were lysed with
1% NP40 (Thermo Fisher Scientiﬁc, Waltham, MA), and bacteria
were recovered by centrifugation (10 min) at 8 000 r · min−1 at 4 °
C. The bacterial pellet was sonicated in 2 mL ice-cold PBS, washed
once in PBS, and transferred to a 96-well U-bottom plate (Thermo
Fisher Scientiﬁc). First, non-speciﬁc binding to protein A was
blocked with rabbit anti-protein A immune sera (1:100) for 30 min
at 4 °C. Bacteria were then incubated with anti-LTA mAb or IgG1
(10 µg · mL−1) for 1 h at 4 °C, washed in PBS, and incubated with
Alexa Fluor 633 (Thermo Fisher Scientiﬁc)-conjugated goat anti-
human IgG for 30 min at 4 °C (Jackson Immunoresearch Labora-
tory, West Grove, PA). Following one wash, live bacteria were
stained for 15min at room temperature with BODIPY FL
Vancomycin and mAb binding was quantiﬁed as above.
Octet afﬁnity measurement
Anti-LTA mAb-binding kinetics to puriﬁed LTA were analyzed using
an Octet 384 instrument with 384 slanted well plates (ForteBio,
Menlo Park, CA). An aminopropylsilane biosensor was ﬁrst loaded
with 100 µg · mL−1 of puriﬁed S. aureus LTA (Sigma-Aldrich) for 300
s. Anti-LTA mAb (7.8–500 nmol · L−1) association was measured for
40 s, followed by a 300 s dissociation into kinetic buffer (ForteBio).
All steps were performed using a 3-mm sensor offset with 0.6 Hz
sensitivity. Data were exported to Prism (GraphPad, La Jolla, CA) for
Global Association/Dissociation afﬁnity curve ﬁtting.
Mouse model of PJI
All animal procedures were approved by the Johns Hopkins
University Animal Care and Use Committee. Six-week-old male
C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) were used in
all experiments. A mouse model of PJI was performed as
previously described.14,15 Brieﬂy, a medial parapatellar approach
was used to access the right distal femur. After dislocating the
patella, a 25-gauge needle was used to ream the distal femoral
medullary canal. Thereafter, a medical-grade Kirschner-wire (0.5
mm diameter × 9mm in length; Modern Grinding, Port Washing-
ton, WI) was inserted in retrograde fashion with approximately 0.5
mm protruding into the knee joint to which was added 2 µL sterile
saline for the sterile control or directly inoculated with 1 × 103
CFU. The patella was relocated and the knee was surgically closed
using two interrupted absorbable sutures.
In vivo BLI
Postsurgical infection was conﬁrmed by direct BLI of bacteria
using the IVIS Lumina III imaging system (PerkinElmer, Hopkinton,
MA). Imaging (large binning and a 5min exposure) was performed
immediately on anesthetized mice (2% isoﬂurane) before surgery
and then on postoperative days 3, 7, 14, and 21. Signal was
quantiﬁed using the Living Image software within a region of
interest (ROI) of 0.5 × 0.75 cm2 centered over the surgical knee and
measured as maximum radiance (photons/second/cm2/steradian).
The limit of detection was 2.5 × 103 photons/s/cm2/sr. After an
infection was established, the right hind limb was cleared of hair,
and a bioluminescent image was acquired (IVIS Spectrum; Perkin
Elmer). An elliptical ROI of 0.74 × 0.98 cm was used to measure
persistent infection.
Radiotracer administration
All animal work was in accordance with AAALAC, IACUC, and was
approved by the Johns Hopkins Animal Care and Use Committee
(Protocol #: MO15M421 and MO14M57). Clinical-grade [18F]FDG
and [18F]NaF were obtained from the Johns Hopkins PET Center
Radiopharmacy, supplied by PETNET Solutions (Siemens Health-
care, Malvern, PA).26 Injectate was assayed using a sodium iodide
CRC-15 dose calibrator and a calibration factor of 439 (Capintec,
Ramsey, NJ). Mice were anesthetized by isoﬂurane (2%) inhalation
and injected intravenously via the retro-orbital sinus with 200 μCi
average activity of tracer diluted to a ﬁnal volume of 100 μL in
isotonic saline. For [18F]FDG, PET/CT was performed following a 1 h
uptake period under continuous isoﬂurane anesthesia. For [18F]
NaF, the mice were scanned following a 40min uptake period
without anesthesia.
Radiolabeled antibodies were prepared as detailed above, and
injectate was assayed using a well counter with a calibration factor
of 517, as determined previously.29 In a volume of 150 µL, 225 µCi
of radiolabeled antibody (approximately 100 µg) was administered
intravenously via the retro-orbital sinus. Mice were serially
scanned (10–20min acquisitions, 350–750 keV energy window)
on days 1, 3, 5, and 7 on a microPET R4 system (Concorde
Microsystems Inc., Knoxville, TN) followed by Faxitron MX-20-DC12
digital X-ray imaging system (Faxitron Bioptics, LLC, Tucson, AZ).
PET/CT imaging
Sequential PET (12min acquisition, 140–700 keV energy window)
and CT scans were performed using the SuperArgus small-animal
integrated PET/CT scanner (Sedecal Systems, Buffalo Grove, IL). CT
parameters for acquisition were 40 kVp and 0.8mA with 2mm
aluminum ﬁltration. The 3D imaging analysis platform Amira
(version 5.0; FEI, Hillsboro, OR) was used to merge the PET and CT
data sets to visualize [18F]-FDG uptake in relation to the surgical site.
PET and high-resolution X-ray imaging
The dedicated microPET R4 system was used to acquire PET scans
for radiolabeled antibodies. List-mode data were acquired using a
gamma-ray energy window of 350–750 keV and a coincidence
timing window of 6 ns. PET image data were corrected for detector
nonuniformity, dead time, random coincidences, and physical
decay. For all static images, scan time was between 10 and 20min.
Data were sorted into 3D histograms by Fourier rebinning, and
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transverse images were reconstructed using a maximum a priori
algorithm to a 128 × 128 × 63 (0.845mm× 0.845mm× 1.211 5mm)
matrix. Data sets were analyzed using the ASIPro VM microPET
analysis software. Volumes of interest were manually deﬁned around
the distal femur, and the injected activity per gram was calculated.
An empirically determined system calibration factor for mice was
used to convert voxel count rates to activity concentrations (in µCi
per mL of tissue). Figures were generated using Amira (version 5.0;
FEI, Hillsboro, OR). Directly after PET scanning, while in the same
position, planar X-ray images of the mice were acquired using the
Faxitron MX-20-DC12 digital X-ray imaging system (Faxitron Bioptics,
LLC, Tucson, AZ).
Statistical analysis
All data with statistics are expressed as mean ± S.E.M. Data were
analyzed using an unpaired one-tailed (BLI and [18F]FDG and [18F]
NaF uptake) or two-tailed (CT volume) Student's t-test with
Welch’s correction or the Holm–Sidak method, with alpha= 0.05,
and each row was analyzed individually, without assuming a
consistent standard deviation. Analysis of variance followed by
Bonferroni’s multiple comparison test was used to assess [89Zr]-
antibody uptake; outliers were removed via analysis of absolute
variance relative to the mean. Pearson’s correlation analysis was
performed in Prism (GraphPad version 7.0d) between PET imaging
of [89Zr]-antibody (using the ratio of uptake in the surgical vs
contralateral leg and fold increase uptake of [18F]FDG and [18F]
NaF) and the standardized uptake value (SUVmean) of [89Zr]-
antibody in the surgical pin leg vs bioluminescent ﬂux values from
the same limb. P-values <0.05 were considered signiﬁcant.
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